Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 4/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 2/20 | 1.00 |
| ▸ | RAF1 | P04049 | 2/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 1.00 |
| ▸ | MAP2K2 | P36507 | 2/20 | 1.00 |
| ▸ | TGFBR2 | P37173 | 2/20 | 1.00 |
| ▸ | NEK2 | P51955 | 2/20 | 1.00 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 1.00 |
| ▸ | TNK2 | Q07912 | 2/20 | 1.00 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 1.00 |
| ▸ | PTK6 | Q13882 | 2/20 | 1.00 |
| ▸ | NEK11 | Q8NG66 | 2/20 | 1.00 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 1.00 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 1/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | PIR | O00625 | 1/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
| ▸ | DCLK1 | O15075 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Plx-4720 SCHEMBL133733 | 1.00 | BRAF (1.00) | BRAFRIPK2RAF1KDRMAP2K2 | |
| Plx-4720 SCHEMBL29537252 | 1.00 | BRAF (1.00) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL298760 | 0.95 | BRAF (0.90) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL298198 | 0.94 | BRAF (0.88) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL7868924 | 0.93 | BRAF (0.88) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL298282 | 0.92 | BRAF (0.84) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL299672 | 0.91 | BRAF (0.83) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL298349 | 0.91 | BRAF (0.83) | BRAFRIPK2RAF1KDRMAP2K2 | |
| Vemurafenib SCHEMBL29355460 | 0.90 | BRAF (1.00) | BRAFRIPK2RAF1KDRMAP2K2 | |
| SCHEMBL12891936 | 0.90 | BRAF (1.00) | BRAFRIPK2RAF1KDRMAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658321-A1 | P-SELECTIN TARGETED NANOPARTICLES AND USES THEREOF | Ramot at Tel-Aviv University Ltd. (IL) | 2025-12-10 | — | — | EP | claimed |
| US-12195771-B2 | Combination chemotherapy for the treatment of cancer | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-01-14 | — | — | US | claimed |
| WO-2024161404-A1 | P-SELECTIN TARGETED NANOPARTICLES AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2024-08-08 | — | — | WO | claimed |
| US-11286469-B2 | Combination chemotherapy for the treatment of cancer | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2022-03-29 | — | — | US | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4658321-A1 | P-SELECTIN TARGETED NANOPARTICLES AND USES THEREOF | Ramot at Tel-Aviv University Ltd. (IL) | 2025-12-10 | — | — | EP | disclosed |
| WO-2024218632-A1 | ERK PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| CN-114026073-B | Quinazolin-4-one derivatives for the treatment of BRAF related diseases and disorders | ARRAY生物制药公司 | 2024-08-23 | — | — | CN | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| CN-118459485-A | Amino-substituted heterocycles for the treatment of cancers with EGFR mutations | 纽威伦特公司 | 2024-08-09 | — | — | CN | disclosed |
| WO-2024161404-A1 | P-SELECTIN TARGETED NANOPARTICLES AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2024-08-08 | — | — | WO | disclosed |
| CN-118021814-A | Combination therapy with EHMT2 inhibitors | EPIZYME股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2022126133-A1 | ALK-5 INHIBITORS AND USES THEREOF | SUMITOMO PHARMA ONCOLOGY,INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| CN-110291089-B | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing liver cell death | 海帕瑞吉尼克斯股份有限公司 | 2022-05-27 | — | — | CN | disclosed |
| EP-3994132-A1 | TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITORS AND USES THEREOF | Sumitomo Dainippon Pharma Oncology, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| EP-3990437-A1 | QUINAZOLIN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | Array Biopharma, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2022052913-A1 | COMPOSITIONS AND METHODS FOR T CELL ENGINEERING | GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD. (CN) | 2022-03-17 | — | — | WO | disclosed |
| WO-2022043558-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022043556-A1 | STABLE RADIOPHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022043557-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) | 2022-03-03 | — | — | WO | disclosed |